Search

everythinglearnresearchcommunity

for

Search:↓

User tried microneedling with min and fin for hair loss, experienced inflamed scalp and dandruff. Recommends proper disinfection of microneedler to avoid issues.

The conversation is about frustration over the delay in phase 2 results for a hair loss treatment called GT20029. One user suspects the treatment may have failed.

Verteporfin and FAK inhibitors being looked at as potential treatments for hair regeneration, with updates on the unofficial off-label human trial being discussed.

The conversation is about finding a legitimate source for RU58841 in Germany, with suggestions including Receptorchem and GeneTherica. Anageninc and Chemyo do not deliver to Germany.

Minoxidil may inhibit collagen synthesis at high concentrations, with anecdotal reports of skin aging but limited research. Dermatologists and other specialists show little interest in studying minoxidil's side effects.

A man with thick, white hair is admired for his genetics, leading to discussions about hair loss and the preference for white hair over balding. Some speculate about the use of treatments like finasteride.

HMI-115 is a new drug developed by Bioinvent and licensed by Bayer, with mixed opinions on its potential effectiveness. Some users are skeptical and prefer proven treatments like Minoxidil, finasteride, and RU58841.

The conversation discusses Fevipiprant, an asthma drug that may block CRTH2 and potentially stop male pattern baldness (MPB) without inhibiting DHT. It also mentions the use of finasteride and dutasteride for hair loss.

Topical antihistamine creams, like diphenhydramine, are being considered for scalp inflammation and itchiness as an adjunct to standard hair loss treatments like minoxidil and finasteride. The user is cautious about oral antihistamines due to potential side effects and is exploring topical options.

Melatonin's effect on aromatase expression is unclear, with studies showing both increases and decreases. Hormonal impacts are complex and inconsistent, similar to changing health advice on other substances.

The conversation discusses the potential of a new hair loss treatment, GT20029, which may prevent hair loss by destroying androgen receptors on the scalp. Users express hope for the treatment's success and speculate on its usage routine, effectiveness, and possible side effects.

The conversation humorously discusses the fictional "Post PP405 Syndrome" and the idea of starting a foundation or cult around it. It mentions skepticism about the effectiveness of PP405 and jokes about future therapies.

The conversation is about hair loss and the conclusion is that genetics play a significant role in hair loss, and lifestyle choices or being a well-adjusted person do not prevent male pattern baldness.

An 18-year-old noticed hair thinning at 17, started finasteride 5 months ago, and saw shedding stop but no regrowth. They suspect male pattern baldness due to family history and are concerned about thinning on the back and sides, possibly due to inflammation.

The user is using testosterone and finasteride to prevent hair loss and is considering adding Primobolan or Masteron, which are DHT-derivatives. They are seeking advice on their genetic risk for male pattern baldness and whether they can safely use these compounds without significant hair loss.

The user observed that stopping nicotine and caffeine improved their scalp health while using oral finasteride. However, relapsing with caffeine and nicotine caused scalp tightness and inflammation.

The user shares their experience with hair loss treatments, including oral finasteride, oral minoxidil, and a topical lotion for dandruff, expressing dissatisfaction with past treatments like PRP and hair transplants. They seek advice on a DNA test to determine suitable medications and express frustration with dermatologists' advice.

DLQ01, a prostaglandin F2α analog, shows promise for hair growth by directly stimulating PGE2/PGF receptors without needing conversion, and can be combined with minoxidil and retinoids like tretinoin for enhanced effectiveness. Minoxidil's efficacy may be reduced by COX-1 inhibitors, but using prostaglandin analogs like Latanoprost or Bimatoprost can help maintain its effectiveness.

Stem cell-related treatments and drugs like RCGD423 and WAY are being tested for hair growth. Clinics are conducting tests on patients who haven't had previous treatments.

Hair loss treatments, specifically 5AR inhibitors, can impact neurosteroids and sexual health. The effects of topical fin/dut on tissue-specific DHT levels are unclear.

Creatine may affect hair loss by reducing PGE2 levels, which could influence hair growth. The discussion highlights the need for more research on this potential mechanism.

Hair loss and potential treatments, primarily focusing on Finasteride and Minoxidil. Other solutions discussed include PRP, dermarolling, LLP, and scalp tension relief.

Some hair loss may be linked to chromosome 20, which isn't affected by DHT blockers like finasteride. Treatments like minoxidil, microneedling, and genetic testing are suggested, but their effectiveness for this type of hair loss is uncertain.

A young female diagnosed with Lichen planopilaris (LPP) experienced years of misdiagnosis and ineffective treatments, including a hair transplant and other procedures. She is considering litigation due to the misdiagnosis and has learned that LPP is chronic, hair loss can be stopped with ongoing medication, but lost hair cannot regrow.

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

The user experienced significant hair regrowth in 5 weeks using Minoxidil, Finasteride, Dutasteride, biotin, collagen, derma stamping, and a mixture of oils, leading others to label them a "hyper responder." Some users advised caution with microneedling frequency to avoid potential scarring.

The user noticed new baby hairs after using sulforaphane but is still experiencing shedding. They are seeking a supplement to stop shedding, possibly grape seed extract.

The use of tropoelastin injections and verteporfin for hair transplant recipients to help regrow donor area hairs, as well as research done on tropoelastin injections restoring elastin in scarred heart tissue and skin. There are discussions about why it is taking so long to get cosmetic mass produced tropoelastin injectables on the market.

Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.

Researchers at the University of Virginia discovered a new group of stem cells in hair follicles that could potentially restore hair growth. The findings suggest that activating these stem cells might offer a new way to combat hair loss, though practical treatments are still years away.